Turn Biosciences was an American startup specializing in anti-aging therapies. Like Life Biosciences, their approach was based on partial epigenetic reprogramming. However, Turn Bio utilized lipid nanoparticles (LNPs) for delivery, which allowed for more scalable production and easier administration. The company was particularly advanced in developing therapies for hair, muscle, and cardiovascular age-related diseases (ARDs). Although Turn Biosciences went bankrupt a few months ago—leaving their patents and technology in limbo—this new acquisition could put several promising therapies back on track, potentially launching Phase I clinical trials before the end of the decade. submitted by /u/Ewig_luftenglanz [link] [comments]